En
.jpg)
Moody's: Teva opioid settlement credit negative
Moody's Investors Service has said that the announcement by Teva Pharmaceutical Industries Ltd. of a proposed framework to resolve outstanding opioid litigation is credit negative because of its adverse effect on the company's earnings and deleveraging. This is primarily because of the costs Teva would incur in supplying $23 billion worth of buprenorphine naloxone tablets - a treatment for opioid dependence - for a period of 10 years, Trend with reference to Globes reports.